{
  "docId": "019de516-a80e-7369-bef2-cb942c391804",
  "docSlug": "7dbeec795af717930d34b2c0014ea723",
  "documentTitle": "Oculis | Results Presentation Deck | 33 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 33,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-a80e-7369-bef2-cb942c391804/7",
  "deckHref": "/decks/019de516-a80e-7369-bef2-cb942c391804",
  "deckJsonHref": "/decks/019de516-a80e-7369-bef2-cb942c391804.json",
  "deckAnchorHref": "/decks/019de516-a80e-7369-bef2-cb942c391804#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.04,
        "y": 0.57
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "365405cd-e29d-45d3-9d5d-8bd3ca2e5b20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de892861-9c07-4ad7-b71a-eb24ca1ee0a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.11,
        "x": 0.85,
        "y": 0.04
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "254bce2d-f936-4274-9204-341e841df7eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.49,
        "x": 0.258,
        "y": 0.25
      },
      "kind": "list",
      "text": "Current treatments include a combination of topical steroid, antibiotic and NSAID\nUp to 12 drops a day¹\n2-6 weeks treatment regimens",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b6ec2fa-2aec-40fb-b292-ea3edadcdba2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.17,
        "w": 0.71,
        "x": 0.258,
        "y": 0.57
      },
      "kind": "list",
      "text": "CME is the most significant cause of decreased vision in patients following cataract surgery²\nClinically significant CME occurs in up to 5.8% of cataract surgeries3 representing ~215K cases in the US, ~400K cases in EU, and 1.6M cases worldwide3,4\nIn 30% of the patients defined as high-risk due to pre-existing conditions (e.g., diabetes, uveitis)5-7, the risk of clinically significant CME following ocular surgery may increase to 56%5",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb4bdac7-331a-4c5f-9104-20f1004039f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.71,
        "x": 0.226,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "There are no approved treatments or prevention for post-surgery CME",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70e93011-5bb0-4ff8-9431-7bb604dd854a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.74,
        "x": 0.226,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "Regimen complexity often leads to low patient compliance and may result in suboptimal treatment outcomes",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b807b0b0-6615-4ad3-bc19-4c66709e5388",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.026,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "CME: cystoid macular edema; IOP: intraocular pressure; NSAID=non-steroidal anti-inflammatory drugs; OCT: Optical coherence tomography. 2. Burling-Phillips L. After Cataract Surgery: Watching for Cystoid Macular Edema. American Academy of Opthamology. 2007. https://www.aao.org/eyenet/article/after-cataract-surgery-watching-cystoid-macular- ed#:~:text=Insidious%20CME., much%20remains%20unknown%20about%20it. 3. CRST Global. Prevention of CME After Cataract Surgery. 2013. https://crstodayeurope.com/articles/2013-julaug/prevention-of- cme-after-cataract-surgery. (Percentage applied to US; EU and world population). 4. Rossi T, et al., BMJ Open Ophthalmol. 2021; 13;6(1):e000464. 5. ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting. 6. Chu CJ, et.al. Ophthalmology. 2016:123:316-323. 7. Erikitola OO, et al. Eye. 2021;35:584-591.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaa5bc16-683c-4a1b-953b-b9fcab5a7e27",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.54,
        "x": 0.026,
        "y": 0.06
      },
      "kind": "title",
      "text": "Current Treatments for Post Ocular Surgery",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2879b484-8d8d-48cb-ad3a-4d725e441192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.74,
        "x": 0.026,
        "y": 0.11
      },
      "kind": "title",
      "text": "Complex regimens with potential complications, especially cystoid macular edema",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47fba5bb-88ed-49e2-8f62-14e2c25cfdbb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "7cd25c33-a016-4533-80a2-0d7ace203823",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the current limitations and challenges of post-ocular surgery treatments (slide 7).",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 10,
      "from": 7,
      "beatId": "bf8d92bd-d10c-44d0-8929-d028af75265a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document further agitates the problem by presenting detailed clinical data on the OPTIMIZE trial and current treatment limitations (slides 7-10).",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5d7f0e87-f17e-4730-84ac-15c62ad2ef1a",
      "evidence": "The document implies the cost of inaction by highlighting the limitations of current treatments and the potential benefits of OCS-01.",
      "position": 0,
      "objective": "What are the consequences of not addressing post-ocular surgery inflammation and pain effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}